New Drug PT00114 Cuts Stress Hormones 56% in Preclinical Trial
Protagenic's PT00114 slashed stress-related cortisol markers and anxiety behaviors in rats, outperforming a standard CRF1 antagonist.
Summary
Protagenic Therapeutics has released early animal data showing its experimental drug PT00114 significantly reduces chronic stress markers. In a 14-day rat stress model, two doses of PT00114 cut stress-hormone levels by over 56% and increased calm exploratory behavior by 282% compared to untreated stressed controls. Notably, a well-known comparison drug in the same class failed to show any effect. PT00114 appears to work through a novel mechanism related to the brain's stress signaling system, potentially explaining why it succeeds where earlier drugs failed. The compound has already passed Phase 1 human safety trials and the company plans further clinical studies in 2027. This is promising for anyone interested in stress biology and mental health as longevity factors.
Detailed Summary
Chronic stress is increasingly recognized as a significant driver of accelerated aging, cardiovascular disease, and cognitive decline — making effective stress-reduction therapeutics a genuine longevity target. Protagenic Therapeutics has now published preclinical data suggesting its lead drug candidate, PT00114, may offer a meaningful advance in this space.
In a rigorous 14-day chronic unpredictable stress model using male Sprague-Dawley rats, PT00114 was administered via two subcutaneous doses on days 12 and 13. The results were striking: stressed animals treated with PT00114 showed a 56.4% reduction in plasma corticosterone — the rodent equivalent of cortisol — compared to stressed, saline-treated controls, with a statistically significant p-value of 0.029. Behavioral testing in an open-field arena showed a 282% increase in time spent in the center zone, a validated measure of reduced anxiety, with no change in total movement, ruling out sedation as the cause.
What makes these findings particularly interesting is the comparison drug's failure. CP-154,526, a well-characterized CRF1 receptor antagonist, showed zero activity on either endpoint regardless of dosing schedule. This mirrors the repeated clinical failures of CRF1 antagonists in human trials — a graveyard of promising compounds that never translated. PT00114 is a synthetic analog of TCAP-1, a naturally occurring peptide, and appears to act upstream of or alongside the CRF signaling pathway rather than directly blocking CRF1 receptors.
From a translational standpoint, PT00114 has already completed single- and multiple-dose Phase 1 human studies with favorable safety results. Protagenic plans to initiate further clinical trials in 2027.
Caveats are important here. This is preclinical data in male rats only, and the history of stress-pathway drugs failing in human trials demands measured expectations. Nonetheless, the novel mechanism and Phase 1 safety clearance make PT00114 a credible candidate to watch for those tracking the stress-longevity intersection.
Key Findings
- PT00114 reduced stress-induced corticosterone by 56.4% versus controls in a 14-day chronic stress rat model.
- Anxiety behavior dropped sharply: time in open-field center zone rose 282% with no sedation effect.
- Standard CRF1 antagonist CP-154,526 showed zero effect, highlighting PT00114's potentially novel mechanism.
- PT00114 has cleared Phase 1 human safety studies; clinical trials planned for 2027.
- Drug may work upstream of the CRF pathway, explaining past failures of direct CRF1 blockers.
Methodology
This is a news report summarizing company-released preclinical data from Protagenic Therapeutics, not a peer-reviewed publication. The source, Longevity.Technology, is a credible specialist outlet but the underlying study has not been independently verified in a journal context. Statistical significance was reported (p < 0.05) for key endpoints.
Study Limitations
Data comes from a company press release based on male rat models only, limiting generalizability to women and humans broadly. CRF1 antagonists have a long history of preclinical promise followed by clinical failure, warranting caution. Independent peer-reviewed publication of the full study data has not yet been confirmed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: